CRISPR Gene Editing
The Bacterial Immune System That Became the Most Powerful Tool in Biology
For billions of years, bacteria have been quietly running a search-and-destroy archive of every virus that ever attacked them — and we only noticed in 2012.
The Idea
CRISPR — Clustered Regularly Interspaced Short Palindromic Repeats — was not invented. It was discovered, already humming away inside single-celled organisms that had been using it for eons. Bacteria, it turns out, clip a small piece of DNA from attacking viruses and file it in their own genome, between those characteristic repeating sequences. If that virus returns, the bacterium produces a molecular 'wanted poster' — a strand of RNA matching the stored snippet — and pairs it with a protein called Cas9, which hunts down the matching viral DNA and cuts it apart. Immunity through memory, at the molecular level. What Jennifer Doudna, Emmanuelle Charpentier, and their colleagues realised — and what won them the Nobel Prize in Chemistry in 2020 — is that this system is programmable. You can hand Cas9 a custom RNA guide of your own design, point it at any DNA sequence you choose, and it will cut there with extraordinary precision. Not roughly. Not approximately. Right there, at the letter you specified. This reframed the entire project of genetic engineering. Previous tools were expensive, slow, and imprecise — blunt instruments by comparison. CRISPR is fast, cheap enough to run in a modest lab, and accurate enough to correct a single misplaced nucleotide among the three billion in a human genome. The question shifted almost overnight from 'Can we edit genes?' to 'What should we edit — and who decides?'
In the World
In 2023, the UK became the first country to approve a CRISPR-based treatment for a human disease. The therapy, called Casgevy, targets sickle cell disease and beta-thalassemia — both caused by mutations in the gene that governs haemoglobin, the protein that carries oxygen in red blood cells. Patients with sickle cell disease spend much of their lives managing pain crises severe enough to hospitalise them, caused by misshapen blood cells that clump and block circulation. The treatment works by reactivating a gene that all of us carry but that switches off shortly after birth: the foetal haemoglobin gene. Patients have their own stem cells extracted, edited in the lab using CRISPR to silence the molecular 'off switch' for foetal haemoglobin, then reinfused. The body begins producing functional haemoglobin again — not corrected adult haemoglobin, but the foetal version, which works just as well. In clinical trials, nearly all participants who received the therapy experienced a complete elimination of severe pain crises for the following year or more. For people who had spent decades living around the rhythms of an unpredictable, debilitating illness, this was not an incremental improvement. It was, for many, a transformation. What makes this moment historically strange is how recently it would have been science fiction — the underlying biological mechanism was only characterised a little over a decade ago, and the first approved human treatment followed within roughly ten years. The pace is almost without precedent in medicine.
Why It Matters
CRISPR sits at a rare intersection: a technology that is simultaneously advancing faster than our ethical frameworks can keep up with, and also genuinely capable of relieving suffering on a large scale. Holding both of those things at once is the intellectual challenge. The treatment approved for sickle cell disease is a vivid illustration of the promise. But the same precision that can correct a mutation in extracted stem cells could, in principle, be applied to embryos — creating changes that would be inherited by every subsequent generation. That line has already been crossed once, controversially, by a researcher in China in 2018, who edited embryos that were then brought to term. The scientific community's reaction was near-universal condemnation, not because the technology failed but because the governance around it had not caught up. Knowing how CRISPR actually works — not just that it 'edits genes' but that it is a repurposed bacterial immune system that can be guided with custom molecular instructions — gives you something more useful than a headline. It gives you the ability to ask sharper questions about what is being proposed, what the risks actually are, and whose interests are shaping the answers.
A Question to Ponder
If you could draw a clear line between CRISPR edits that relieve suffering and those that constitute enhancement — would that line hold, and who would you trust to draw it?
Get a new one of these every morning.
Start learning with Thinkable